• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alto Neuroscience Inc.

    4/1/25 4:20:08 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANRO alert in real time by email
    DEFA14A 1 d936566ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.)

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    ALTO NEUROSCIENCE, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    LOGO

    This communication presents only an Your Vote Counts! overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot ALTO NEUROSCIENCE, INC. use this notice to vote your shares. We encourage you to access and review all 2025 Annual Meeting of the important information contained Vote in advance by May 12, 2025 in the proxy materials before voting. 11:59 PM ET ALTO NEUROSCIENCE, INC. 650 CASTRO STREET, SUITE 450 MOUNTAIN VIEW, CA 94041 V65340-P22265 You invested in ALTO NEUROSCIENCE, INC. and it’s time to vote! Stockholders of record as of the close of business on March 17, 2025 have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 13, 2025. Get informed before you vote View the 2024 Annual Report on Form 10-K, Notice, and Proxy Statement online at www.ProxyVote.com, OR you can receive a free paper or email copy of the material(s) by requesting prior to April 29, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and May 13, 2025 8:30 a.m., Eastern Time vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/ANRO2025 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1. To elect the Board’s Class I Director nominee, Husseini Manji, to the Board of Directors to hold office until the 2028 Annual Meeting of Stockholders. Nominee: 1a. Husseini Manji For 2. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent For registered public accounting firm of the Company for the year ending December 31, 2025. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment, continuation, or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V65341-P22265 

    Get the next $ANRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANRO

    DatePrice TargetRatingAnalyst
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    9/3/2024$29.00Outperform
    Wedbush
    2/27/2024Outperform
    William Blair
    2/27/2024Outperform
    TD Cowen
    2/27/2024$32.00Outperform
    Robert W. Baird
    2/27/2024$33.00Buy
    Jefferies
    2/27/2024$32.00Buy
    Stifel
    More analyst ratings

    $ANRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alto Neuroscience downgraded by Wedbush with a new price target

      Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

      10/23/24 7:37:30 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

      10/23/24 6:52:50 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Alto Neuroscience with a new price target

      Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

      9/3/24 7:41:31 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Manji Husseini

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      5/15/25 4:16:52 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cox Christopher Nixon

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      5/15/25 4:16:40 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director York Gwill

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      5/15/25 4:16:18 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

      – Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed Phase 2a and ongoing Phase 2b trial of ALTO-300 in MDD underscore favorable tolerability profile for 25mg dose – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025. ALTO-300, also known as agomelatine, is an oral, s

      5/29/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience to Participate in Upcoming Investor Conferences

      Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thursday, June 5, 2025, at 2:00 pm ET Location: New York Marriott Marquis H.C. Wainwright 6th Annual Neuro Perspectives Conference, June 16-17th 2025: Format: Fireside chat and one-on-one investor meetings Presentation avail

      5/28/25 8:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Financials

    Live finance-specific insights

    See more
    • Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

      – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

      6/3/25 6:03:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      7/11/24 4:15:04 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

      4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

      4/1/24 4:15:30 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    SEC Filings

    See more
    • Alto Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

      6/3/25 6:34:52 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Alto Neuroscience Inc.

      SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      5/15/25 4:26:21 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Alto Neuroscience Inc.

      SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      5/15/25 3:19:13 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

      SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 5:46:11 PM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/14/24 7:00:29 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Alto Neuroscience Inc.

      SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

      11/12/24 9:50:14 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Christopher Nixon Cox Named Chairman of High-Trend International Group

      SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

      3/13/25 9:00:00 AM ET
      $ANRO
      $HTCO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Marine Transportation
      Consumer Discretionary
    • Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

      – Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

      5/21/24 8:05:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

      – Experienced Medical and Executive Leader, Dr. Radhakrishnan served as Group SVP and Chief Medical Officer of Biogen, responsible for the Worldwide Medical function – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company's board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies. "Maha joins our Board at a pivotal moment for Alto, as we continu

      3/11/24 8:05:00 AM ET
      $ANRO
      Biotechnology: Pharmaceutical Preparations
      Health Care